UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose

British journal of clinical pharmacology, 2020-02, Vol.86 (2), p.258-273

2020

Volltextzugriff (PDF)

Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial

The journal of clinical endocrinology and metabolism, 2012-10, Vol.97 (10), p.3495-3503

2012

Volltextzugriff (PDF)

Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost‐effectiveness study

British journal of clinical pharmacology, 2019-09, Vol.85 (9), p.1994-2001

2019

Volltextzugriff (PDF)

Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS

Biomedical chromatography, 2020-03, Vol.34 (3), p.e4758-n/a

2020

Volltextzugriff (PDF)

Clinical pharmacokinetics of tyrosine kinase inhibitors

Cancer treatment reviews, 2009-12, Vol.35 (8), p.692-706

2009

Volltextzugriff (PDF)

Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites

Cancer chemotherapy and pharmacology, 2022-02, Vol.89 (2), p.271-274

2022

Volltextzugriff (PDF)

Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor—Darolutamide

Clinical pharmacokinetics, 2023-08, Vol.62 (8), p.1049-1061

2023

Volltextzugriff (PDF)

Effect of Aprepitant on Etoposide Pharmacokinetics in Patients with Testicular Cancer: A Pharmacokinetic Study to Determine the Absence of a Clinically Relevant Interaction

Clinical pharmacology and therapeutics, 2024-01, Vol.115 (1), p.135-138

2024

Volltextzugriff (PDF)

The impact of a 1‐hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure

International journal of cancer, 2021-06, Vol.148 (11), p.2799-2806

2021

Volltextzugriff (PDF)

Drug–drug interaction potential in men treated with enzalutamide: Mind the gap

British journal of clinical pharmacology, 2018-01, Vol.84 (1), p.122-129

2018

Volltextzugriff (PDF)

Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib

British journal of clinical pharmacology, 2017-10, Vol.83 (10), p.2195-2204

2017

Volltextzugriff (PDF)

The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour

British journal of clinical pharmacology, 2021-02, Vol.87 (2), p.326-335

2021

Volltextzugriff (PDF)

Results of the first international quality control programme for oral targeted oncolytics

British journal of clinical pharmacology, 2024-01, Vol.90 (1), p.336-343

2024

Volltextzugriff (PDF)

Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials

Clinical cancer research, 2019-03, Vol.25 (5), p.1479-1485

2019

Volltextzugriff (PDF)

The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer

British journal of clinical pharmacology, 2022-03, Vol.88 (3), p.1170-1178

2022

Volltextzugriff (PDF)

Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report

Cancer chemotherapy and pharmacology, 2021-07, Vol.88 (1), p.165-168

2021

Volltextzugriff (PDF)

Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line abiraterone acetate and prednisone treatment

Molecular oncology, 2021-09, Vol.15 (9), p.2453-2465

2021

Volltextzugriff (PDF)

Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study

Clinical chemistry (Baltimore, Md.), 2020-06, Vol.66 (6), p.842-851

2020

Volltextzugriff (PDF)

Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer

Biomedicine & pharmacotherapy, 2022-09, Vol.153, p.113393-113393, Article 113393

2022

Volltextzugriff (PDF)

Reply to ‘Hyperthermic intraperitoneal chemotherapy with oxaliplatin—Still not standard of care for patients with colorectal peritoneal metastases’ by Julianov and Saroglu

British journal of clinical pharmacology, 2019-08, Vol.85 (8), p.1848-1849

2019

Volltextzugriff (PDF)

mTOR inhibitor‐induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm

International journal of cancer, 2016-05, Vol.138 (10), p.2312-2321

2016

Volltextzugriff (PDF)

The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients

Cancer chemotherapy and pharmacology, 2020-04, Vol.85 (4), p.753-760

2020

Volltextzugriff (PDF)

Clinical utility of emerging biomarkers in prostate cancer liquid biopsies

Expert review of molecular diagnostics, 2020-02, Vol.20 (2), p.219-230

2020

Volltextzugriff (PDF)

Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure

British journal of clinical pharmacology, 2019-01, Vol.85 (1), p.47-58

2019

Volltextzugriff (PDF)

A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration‐resistant metastatic prostate cancer

British journal of clinical pharmacology, 2018-05, Vol.84 (5), p.1064-1067

2018

Volltextzugriff (PDF)

1 – 25 von 138

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(132)
Mit Volltextzugriff
(123)

Publikationsform

Artikel
(135)
Berichte
(3)

Sprache

Englisch
(135)
Niederländisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(105)
Life Sciences & Biomedicine
(104)
Humans
(77)
Oncology
(60)
Pharmacology & Pharmacy
(50)
Male
(45)
Pharmacokinetics
(41)
Aged
(37)
Female
(35)
Middle Aged
(33)
Adult
(26)
Patients
(21)
Medicine
(20)
Medicine & Public Health
(20)
Pharmacology/toxicology
(20)
Antineoplastic Agents - Pharmacokinetics
(19)
Drug Dosages
(17)
Treatment Outcome
(17)
Toxicity
(16)
Antineoplastic Agents - Administration & Dosage
(15)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose

Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial

Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost‐effectiveness study

Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS

Clinical pharmacokinetics of tyrosine kinase inhibitors

Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites

Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor—Darolutamide

Effect of Aprepitant on Etoposide Pharmacokinetics in Patients with Testicular Cancer: A Pharmacokinetic Study to Determine the Absence of a Clinically Relevant Interaction

The impact of a 1‐hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure

Drug–drug interaction potential in men treated with enzalutamide: Mind the gap

Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib

The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour

Results of the first international quality control programme for oral targeted oncolytics

Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials

The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer

Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report

Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line abiraterone acetate and prednisone treatment

Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study

Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer

Reply to ‘Hyperthermic intraperitoneal chemotherapy with oxaliplatin—Still not standard of care for patients with colorectal peritoneal metastases’ by Julianov and Saroglu

mTOR inhibitor‐induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm

The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients

Clinical utility of emerging biomarkers in prostate cancer liquid biopsies

Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure

A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration‐resistant metastatic prostate cancer

Suchergebnisse filtern